Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aduro Biotech (ADRO)

Aduro Biotech (ADRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 236,614
  • Shares Outstanding, K 16,212
  • Annual Sales, $ 17,260 K
  • Annual Income, $ -82,370 K
  • 60-Month Beta 0.40
  • Price/Sales 13.16
  • Price/Cash Flow N/A
  • Price/Book 5.08
Trade ADRO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/05/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.90
  • Number of Estimates 3
  • High Estimate -0.80
  • Low Estimate -0.95
  • Prior Year -1.30
  • Growth Rate Est. (year over year) +30.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.00 +32.68%
on 09/24/20
15.73 -7.21%
on 10/02/20
+1.30 (+9.74%)
since 09/04/20
3-Month
11.00 +32.68%
on 09/24/20
17.20 -15.15%
on 08/18/20
+2.10 (+16.76%)
since 07/02/20
52-Week
4.51 +223.94%
on 10/25/19
20.20 -27.75%
on 02/20/20
+9.55 (+189.01%)
since 10/04/19

Most Recent Stories

More News
Europe Cancer Vaccines Markets, 2019-2020 & 2027 - Dendritic Cells Cancer Vaccines Segment to Grow at Fastest Rate

, /PRNewswire/ -- The report has been added to offering.

ADRO : 14.60 (+4.18%)
BMY : 61.27 (-0.58%)
GSK : 34.09 (+1.07%)
OBMP : 2.7500 (-1.79%)
PFE : 33.51 (-0.53%)
Cancer Vaccines Global Market Report 2020-30: COVID-19 Growth and Change

Reportlinker.com announces the release of the report "Cancer Vaccines Global Market Report 2020-30: COVID-19 Growth and Change" - https://www.reportlinker.com/p05995337/?utm_source=GNW

ADRO : 14.60 (+4.18%)
CSLLY : 106.1300 (-0.33%)
GSK : 34.09 (+1.07%)
MRK : 72.85 (+0.65%)
North America Cancer Vaccines Market Report 2020-2027 Featuring Leading Players - AstraZeneca, GSK, Aduro Biotech, Pfizer, Sanofi, Bristol-Myers Squibb, Moderna, OncBioMune, MaxiVAX, Nouscom

, /PRNewswire/ -- The report has been added to offering.

ADRO : 14.60 (+4.18%)
BMY : 61.27 (-0.58%)
Aduro Biotech: 3Q Earnings Snapshot

BERKELEY, Calif. (AP) _ Aduro Biotech Inc. (KDNY) on Thursday reported a loss of $14.5 million in its third quarter.

ADRO : 14.60 (+4.18%)
Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing

Combined Company Will Have Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol "KDNY"

ADRO : 14.60 (+4.18%)
KDNY : 17.36 (+0.75%)
Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics

One-for-Five Reverse Stock Split to be Effective October 2, 2020

ADRO : 14.60 (+4.18%)
World Recurrent or Metastatic Head and Neck Cancer Pipeline Insight 2020 with Profiles of Key Players Aduro Biotech, Inc., AstraZeneca, MedImmune LLC and Cue Biopharma

The "Recurrent or Metastatic Head and Neck cancer - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

ADRO : 14.60 (+4.18%)
Chinook Therapeutics Announces $106 Million Private Placement Financing to Advance Precision Medicines for Kidney Disease

Chinook Therapeutics, Inc., a privately held clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced...

ADRO : 14.60 (+4.18%)
Global Cancer Immunotherapy Market Analysis & Forecast to 2023: Profiles of Key Players Aduro BioTech, Amgen, Advaxis, Biogen Idec, GlobeImmune and More

, /PRNewswire/ -- The report has been added to offering.

ADRO : 14.60 (+4.18%)
AMGN : 225.69 (-0.59%)
Aduro Biotech (ADRO) Reports Q2 Loss, Tops Revenue Estimates

Aduro Biotech (ADRO) delivered earnings and revenue surprises of -10.53% and 76.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

ADRO : 14.60 (+4.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aduro Biotech, Inc. is an immunotherapy company. The Company develops technology and vaccines for the treatment of cancer and mesothelin-expressing tumors. Its product pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX which are in different clinical trial. Aduro Biotech, Inc. is...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 15.40
1st Resistance Point 15.00
Last Price 14.60
1st Support Level 14.06
2nd Support Level 13.52
3rd Support Level N/A

See More

52-Week High 20.20
Last Price 14.60
Fibonacci 61.8% 14.20
Fibonacci 50% 12.35
Fibonacci 38.2% 10.50
52-Week Low 4.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar